

Fig. S5. Western Blot. BTRT cells grown in 3D Matrigel culture were treated with vehicle, AMD3100 (10 $\mu$ M), trastuzumab (20  $\mu$ g/ml), or their combination. SDF-1 $\alpha$  (4 ng/ml) was added at the same time (Material and Methods). A polypeptide that was designed as a CXCR4 antagonist but did not show biological function in the HER2+ breast cancer cells was used as a negative control (NC).